Answers are grounded in this paper and cite their sources.
Evaluates IV-EVE's pharmacokinetics in rats, suggesting advantages for advanced cancer treatment.
Background: Oral everolimus (Oral-EVE; EVE, Afinitor®) is an effective therapy for multiple malignancies, including HR-positive/HER2-negative breast cancer, but its clinical use is limited by low and variable oral bioavailability as well as extensive first-pass metabolism. IV-EVE is a Deciparticle™ intravenous formulation of everolimus developed to bypass gastrointestinal absorption and improve systemic pharmacokinetic (PK) predictability. Methods: In vitro ADME properties were assessed across multiple species. IV-EVE (Intravenous EVE, Sapu003) and EVE demonstrated comparable plasma protein binding, metabolic stability, and CYP-mediated metabolism. Pharmacokinetics, tissue distribution, metabolism, and excretion of IV-EVE were evaluated following intravenous administration in rats, with Oral-EVE as a comparator. Results: Elimination of intact everolimus was minimal following either route of administration and occurred predominantly through metabolic biliary/fecal pathways. Compared with Oral-EVE, IV-EVE produced substantially higher and more consistent systemic exposure while maintaining comparable elimination half-lives. Intravenous administration resulted in broad tissue distribution without the marked gastrointestinal accumulation observed following oral dosing. Repeat-dose toxicology studies in rats demonstrated no treatment-related gastric pathology following intravenous administration. Conclusions: These findings suggest that intravenous administration may overcome limitations associated with oral delivery and support the clinical evaluation of IV-EVE in patients with advanced malignancies.
No takes yet. Share an insight, caveat, or question.
Chang et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: